Table 1 Previous literature reports of IFN-α-induced rheumatoid arthritis in patients with CHC
Age | Sex | Treatment | Onset | Biochemical abnormalities | Treatment and outcome | |
|---|---|---|---|---|---|---|
Sood et al.[12] | 47 | W | Recombinant IFN-α-2b + RIB | 20 weeks after starting antiviral therapy | ESR↑, ANA-, RF+ | NSAIDs |
No interruption of antiviral therapy | ||||||
Ionescu et al.[13] | 40 | W | PEG-IFN-α-2b + RIB | 45 weeks after starting antiviral therapy | ESR↑, RF+, Fibrinogen ↑, IgG ↑ | Analgesics and NSAIDs |
PEG-IFN-α-2a + RIB | 10 months after re-treatment for relapsing CHC | HLA B27- HLA DR3/4+ | Regression after cessation of antivirals | |||
Yang et al.[14] | 54 | M | PEG-IFN-α-2a + RIB | 18 weeks after starting antiviral therapy | ESR↑, ANA-, RF-, Anti-CCP Ab+, CRP ↑, | Ibuprofen, celecoxib and tramadol, then switch to hydroxychloroquine and sulfasalazine |
Izumi et al.[11] | 48 | M | PEG-IFN-α + RIB | 2 months after cessation of antivirals | ANA+, RF-, ESR↑, Anti-CCP Ab+, BAFF↑ | Methotrexate and sulfasalazine |